Clinical trials: CAR-T
Hematological Malignancies
Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
Clinical trial for the safety and efficacy of sequential radiotherapy with CAR-T cells in the treatment of relapsed and refractory hematological malignancies with extramedullary lesions
- Trial name
- NCT04790747
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
AML
Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML
This is an open label, phase I study to assess the safety and efficacy of ADGRE2 CAR-T in patients with relapsed and refractory acute myeloid leukemia
- Trial name
- NCT05463640
- Testing
- ADGRE2 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Hematologic Diseases
Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
To determine the safety, toxicity, and maximum tolerated dose (MTD) of CD19/CD20 bispecific CAR-T cells with 4-1BB and mutated CD28 costimulatory domains (20-19 Tan BB06z) in patients with relapsed or refractory CD19+ aggressive…
- Trial name
- NCT07701889
- Testing
- 20-19 Tan BB06oz CAR T
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial.
- Trial name
- NCT05509855
- Testing
- Genetic: WU-CART-007
- Where
- 5 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Allotera Therapeutics
Myeloid Malignancies
A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies
The overall purpose of this study is to explore the therapeutic effect of LeY-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of myeloid malignancies.
- Trial name
- NCT02958384
- Testing
- Anti-LeY-CAR-transduced T cells
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Southwest Hospital, China
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL), Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This is a single-arm, open-label, phase I study (safety and dose escalation) of autologous Chimeric Antigen Receptor (CAR) T-cells targeting CD19 in patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL).
- Trial name
- NCT04653493
- Testing
- CD19 CAR engineered autologous T-cells, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Iran
- Volunteers
- 22 people
- Sponsor
- Sabz Biomedicals
Pediatric Solid Tumor, Germ Cell Tumor
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT03618381
- Testing
- second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Seattle Children's Hospital
Plasma Cell Tumors
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
This study is a multi-center, non-randomized, single-arm, open clinical trial.
- Trial name
- NCT04665076
- Testing
- Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory…
- Trial name
- NCT06173518
- Testing
- AUTO1
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Autolus Limited